01 Increasing Development of Specialized Plasma-Derived Therapeutics The plasma therapy market is increasingly focused on developing specialized plasma-derived medicines for the treatment of immunological, neurological, hematological, and other serious medical conditions. Manufacturers are expanding therapeutic portfolios and exploring new applications for plasma-derived proteins to address unmet patient needs. In March 2025, plasma-derived therapeutics manufacturers continued advancing specialized treatment portfolios for patients with complex immunological, neurological, and chronic medical conditions.
02 Growing Adoption of Advanced Plasma Fractionation and Manufacturing Technologies Automation, improved purification processes, and optimized manufacturing systems can help manufacturers enhance production efficiency and maintain high product-quality standards. This trend is supporting technological modernization across plasma processing and manufacturing operations. In July 2025, plasma therapy manufacturers continued investing in advanced fractionation, purification, automation, and manufacturing technologies to improve production efficiency and operational performance.
01 Growing Prevalence of Immunological and Chronic Diseases The increasing prevalence of immune deficiencies, autoimmune disorders, neurological conditions, and other chronic diseases is supporting demand for plasma-derived therapies. The growing patient population requiring specialized therapies therefore represents a fundamental driver for the plasma therapy market.
01 High Cost of Plasma Collection and Therapeutic Production Plasma-derived therapies require extensive collection, screening, testing, fractionation, purification, and quality-control processes. Maintaining specialized collection centers and highly regulated manufacturing facilities can result in substantial operational expenses. These high production costs can contribute to expensive treatment prices and create affordability challenges for healthcare systems and patients.
01 Increasing Demand for Plasma-Derived Therapies in Emerging Healthcare Markets Growing healthcare investment and improving access to specialized medical treatments are creating opportunities for plasma therapy providers in emerging markets. Expanding diagnostic capabilities and greater awareness of immunological and rare diseases can increase the identification of patients requiring plasma-derived therapies. This expansion of healthcare access represents an important growth opportunity for market participants.
01 Maintaining a Reliable and Sustainable Plasma Supply Fluctuations in donor participation, collection capacity, regulatory requirements, and supply-chain operations can affect the availability of raw plasma for therapeutic manufacturing. Maintaining a reliable and sustainable plasma supply while meeting growing global demand remains a significant challenge for the market.
March 2026 Takeda expanded its plasma-derived therapies portfolio with continued investments in plasma collection, manufacturing capabilities, and treatments for immune deficiencies and rare diseases.
September 2025 CSL Behring expanded its plasma-derived medicine portfolio through advancements in immunoglobulin therapies and manufacturing technologies to support increasing patient demand.
May 2025 Grifols strengthened its plasma therapy operations with new plasma collection initiatives and production improvements to enhance the availability of plasma-derived treatments.